ProQR Therapeutics N.V

(NASDAQ:PRQR)

Latest On ProQR Therapeutics N.V (PRQR):

Date/Time Type Description Signal Details
2023-05-16 17:55 ESTNewsProQR GAAP EPS of -€0.11, revenue of €0.66MN/A
2022-12-22 20:02 ESTNewsEli Lilly sends ProQR 35% higher after expanding RNA editing dealN/A
2022-12-22 20:01 ESTNewsProQR adds 75% as Cantor upgrades on expanded deal with Eli LillyN/A
2022-11-09 10:56 ESTNewsProQR GAAP EPS of -€0.34, revenue of €0.96MN/A
2022-10-04 20:28 ESTNewsAstraZeneca – LogicBio deal indicates more such takeovers are ahead – CantorN/A
2022-08-12 23:58 ESTNewsProQR upgraded at Raymond James on RNA-editing platformN/A
2022-08-11 14:21 ESTNewsProQR says EU regulator seeks additional trial for lead candidateN/A
2022-08-04 15:41 ESTNewsProQR GAAP EPS of -$0.21 beats by €0.02, revenue of €1.02M beats by €0.07MN/A
2022-05-06 06:40 ESTNewsProQR GAAP EPS of -€0.20, revenue of €1.23MN/A
2022-04-30 05:44 ESTNewsProQR Therapeutics (PRQR) Investor Presentation - SlideshowN/A
2022-02-24 17:37 ESTNewsProQR GAAP EPS of -€0.26, revenue of €0.24MN/A
2022-02-15 09:10 ESTNewsProQR cut to Neutral at Citi after “puzzling” trial results for RNA therapyN/A
2022-02-11 08:02 ESTNewsProQR says trial for sepofarsen in Leber congenital amaurosis did not meet main goalN/A
2022-01-04 17:14 ESTNewsProQR Therapeutics expects phase 2/3 trial data of eye disorder RNA therapy in Q1N/A
2021-12-30 17:10 ESTNewsProQR amends convertible debt financing agreement with Pontifax Ventures and Kreos CapitalN/A
2021-12-16 12:25 ESTNewsDosing underway in ProQR Therapeutics' late-stage QR-421a trial for retinitis pigmentosaN/A
2021-10-01 20:00 ESTNewsInvestment Case On ProQR Therapeutics Gets More EnticingN/A
2021-09-29 21:43 ESTNewsProQR reaches a six month high after Editas data for gene editing candidateN/A
2021-09-09 10:16 ESTNewsProQR Therapeutics teams up with Eli Lilly in potential $1.25B research collaborationN/A
2021-09-09 10:15 ESTNewsPRQR, LULU, BASE and RPHM among after hours moversN/A
2021-07-21 20:16 ESTNewsProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal DataN/A
2021-05-06 17:44 ESTNewsProQR reports Q1 resultsN/A
2021-05-05 01:41 ESTNewsProQR shares rise after inking Yarrow Biotechnology dealN/A
2021-05-04 04:26 ESTNewsProQR Therapeutics offers a de-risked opportunity: StifelN/A
2021-04-13 18:50 ESTNewsProQR's sepofarsen shows promise in blindness studyN/A
2021-03-31 06:52 ESTNewsProQR proposes capital raiseN/A
2021-03-31 06:51 ESTNewsProQR raises $90M capital via share offeringN/A
2021-03-25 19:36 ESTNewsProQR Therapeutics up 36% following price target increase at CitiN/A
2021-03-24 23:43 ESTNewsProQR Therapeutics’ RNA therapy for Usher syndrome to reach pivotal trials (Updated)N/A
2021-03-18 05:33 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.22 to $21.12.Neutral
2021-03-13 20:26 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.27 to $21.22.Neutral
2021-03-13 04:17 ESTAnalyst RatingThe Analyst Target Price has increased from $20.93 to $21.27.Buy
2021-03-12 04:30 ESTAnalyst RatingThe Analyst Target Price has increased from $20.88 to $20.93.Buy
2021-03-11 00:36 ESTAnalyst RatingThe Analyst Target Price has increased from $20.8 to $20.88.Buy
2021-03-10 17:45 ESTNewsPounding The Table For ProQR TherapeuticsN/A
2021-03-10 04:36 ESTAnalyst RatingThe Analyst Target Price has decreased from $20.93 to $20.8.Neutral
2021-03-09 00:26 ESTAnalyst RatingThe Analyst Target Price has increased from $20.9 to $20.93.Buy
2021-03-07 12:24 ESTAnalyst RatingThe Analyst Target Price has decreased from $21 to $20.9.Neutral
2021-03-06 00:37 ESTAnalyst RatingThe Analyst Target Price has increased from $20.94 to $21.Buy
2021-03-05 12:14 ESTAnalyst RatingThe Analyst Target Price has decreased from $21 to $20.94.Neutral
2021-03-04 00:40 ESTAnalyst RatingThe Analyst Target Price has increased from $20.94 to $21.Buy
2021-03-03 00:52 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.01 to $20.94.Neutral
2021-03-02 00:33 ESTAnalyst RatingThe Analyst Target Price has increased from $20.98 to $21.01.Buy
2021-03-01 12:13 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.17 to $20.98.Neutral
2021-02-28 00:25 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.33 to $21.17.Neutral
2021-02-27 00:29 ESTFinancialsCompany financials have been released.Neutral
2021-02-27 00:29 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.35 to $21.33.Neutral
2021-02-26 16:11 ESTAnalyst RatingThe Analyst Target Price has decreased from $21.57 to $21.35.Neutral
2021-02-26 16:11 ESTEarnings EstimateAn EPS average of -$1.33 is estimated for the 2022 year.Sell
2021-02-26 16:11 ESTEarnings EstimateAn EPS average of -$0.33 is estimated for the quarter ending on June 30, 2021.Sell

About ProQR Therapeutics N.V (PRQR):

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase 1/2 stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase 1/2 aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial corneal dystrophy. It has a license agreement with General Hospital Corporation, Radboud University Medical Center, Inserm Transfert SA, and Leiden University Medical Center. ProQR Therapeutics N.V. was founded in 2012 and is headquartered in Leiden, the Netherlands.

PRQR Quotes by TradingView

See Advanced Chart

General

  • Name ProQR Therapeutics N.V
  • Symbol PRQR
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Fiscal Year EndDecember
  • IPO Date2014-09-18
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.proqr.com
View More

Valuation

  • Price/Book (Most Recent Quarter) 3.66
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$1.23
  • Next Year EPS Estimate -$1.37
  • Next Quarter EPS Estimate -$0.32
  • Return on Assets -24%
  • Return on Equity -62%
  • Earnings Per Share -$1.31
  • Revenue Per Share $0
  • Gross Profit 9.45 million
  • Quarterly Earnings Growth -37.7%
View More

Highlights

  • Market Capitalization 268.61 million
  • Analyst Target Price $21.12
  • Book Value Per Share $3.09
View More

Share Statistics

  • Shares Outstanding 50.2 million
  • Shares Float 36.74 million
  • % Held by Insiders 295%
  • % Held by Institutions 69.26%
  • Shares Short 899379
  • Shares Short Prior Month 910866
  • Short Ratio 1.11
  • Short % of Float 2%
  • Short % of Shares Outstanding 2%
View More

Technicals

  • Beta 0.46
  • 52 Week High $7.54
  • 52 Week Low $3.6
  • 50 Day Moving Average 4.87
  • 200 Day Moving Average 4.6
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

ProQR Therapeutics N.V (PRQR) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

ProQR Therapeutics N.V (PRQR) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-02-25$N/A-$0.32-$0.31-1.57%
2020-09-302020-11-16$N/A-$0.31-$0.3921.7%
2020-06-302020-08-06$N/A-$0.09-$0.3573.13%
2020-03-312020-05-07$N/A-$0.35-$0.363.87%
2019-12-312020-02-26$475389.62-$0.42-$0.37-14.61%
2019-09-302019-11-06$577656.68-$0.34-$0.389.54%
2019-06-302019-08-07$639627.36-$0.34-$0.4321.19%
2019-03-312019-05-08$466472.3-$0.40-$0.38-5.53%
2018-12-312019-02-27$1.33 million-$0.38-$0.30-26.94%
2018-09-302018-11-07$3.42 million-$0.21-$0.3134.24%
2018-06-302018-08-08$1 million-$0.27-$0.4743.21%
2018-03-312018-05-09$613851.64-$0.40-$0.40-0.05%
2017-12-312018-02-28$635000-$0.48-$0.45-6.53%
2017-09-302017-11-20$411000-$0.49-$0.501.48%
2017-06-302017-08-16$331000-$0.55-$0.51-8.41%
2017-03-312017-05-17$420000-$0.50-$0.511.53%
2016-12-312017-02-28$519000-$0.40-$0.5324.03%
2016-09-302016-11-14$-223000-$0.46-$0.5415.38%
2016-06-302016-08-17$625000-$0.48-$0.48-0.64%
2016-03-312016-05-18$785000-$0.50-$0.41-22.18%
2015-12-312016-02-17$971000-$0.29-$0.3822.83%
2015-09-302015-11-23$1.33 million-$0.30-$0.26-15.38%
2015-06-302015-08-19$848000-$0.41-$0.34-20.59%
2015-03-312015-05-21$363000$0.01-$0.26103.85%
2014-12-312015-02-26$374000-$0.34-$0.28-21.43%
2014-09-302014-11-24$N/A-$0.57-$0.47-21.28%

ProQR Therapeutics N.V (PRQR) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development N/A N/A N/A N/A 15.62 million
Income Before Tax N/A N/A N/A N/A -20.75 million
Selling General Administrative N/A N/A N/A N/A 4.39 million
Gross Profit N/A N/A N/A N/A 475389.62
Ebit N/A N/A N/A N/A -19.54 million
Operating Income N/A N/A N/A N/A -19.54 million
Income Tax Expense 38000 75000 11000 N/A 76241.73
Total Revenue N/A N/A N/A N/A 475389.62
Cost of Revenue N/A N/A N/A N/A N/A
Total Other Income Expense Net N/A N/A N/A N/A -1.22 million
Net Income From Continuing Operations N/A N/A N/A N/A -20.83 million
Net Income Applicable to Common Shares -13.22 million -13.18 million -4.11 million -16.06 million -20.78 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities N/A N/A N/A N/A N/A
Total Cash Flow from Investing Activities -264000 -344000 -198000 -267967.26 -34877.38
Net Borrowings 13.24 million 249000 88000 1.82 million -316076.29
Total Cash Flow from Financial Activities N/A N/A N/A 56.29 million -313896.46
Change to Operating Activities -246000 -907000 -2.2 million 43726.88 2.96 million
Change in Cash N/A N/A N/A 41.66 million -8.36 million
Total Cash from Operating Activities -9.81 million -10.49 million -15.01 million -13.41 million -9.56 million
Depreciation N/A N/A N/A 570691.78 551498.64
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A N/A N/A N/A N/A
Change to Net Income 2.97 million -6 million 2.73 million 7.06 million 155858.31
Capital Expenditures N/A N/A N/A 267967.26 34877.38
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities N/A N/A N/A N/A 26.57 million
Total Stockholder Equity N/A N/A N/A N/A 105.76 million
Other Current Liabilities 7.66 million 8.11 million N/A N/A 10.75 million
Total Assets N/A N/A N/A N/A 131.78 million
Common Stock 57.09 million 68.63 million 80.09 million 81.87 million 105.76 million
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings N/A N/A N/A N/A N/A
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A N/A N/A N/A
Cash N/A N/A N/A N/A 125.52 million
Total Current Liabilities 10.3 million 10.82 million N/A N/A 12.33 million
Other Stockholder Equity N/A N/A N/A N/A N/A
Property, Plant & Equipment 18.6 million 17.88 million 2.1 million 2.29 million 2.74 million
Total Current Assets 80.02 million 92.16 million N/A N/A 128.56 million
Long Term Investments N/A N/A N/A N/A 480995.63
Net Tangible Assets 57.09 million 68.63 million 80.09 million 81.87 million 105.76 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A 14.25 million
Inventory N/A N/A N/A N/A N/A
Accounts Payable 221000 291000 N/A N/A 498934.86

ProQR Therapeutics N.V (PRQR) Chart:

ProQR Therapeutics N.V (PRQR) News:

Below you will find a list of latest news for ProQR Therapeutics N.V (PRQR) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

ProQR Therapeutics N.V (PRQR) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-04-172.50.45CALL0 30FALSE00
2025-04-1750CALL0 00FALSE00
2025-04-177.50CALL0 00FALSE00
2025-04-172.51PUT0 300TRUE00
2025-04-1750PUT0 0105.21TRUE00
2025-04-177.55.7PUT0 1125.3TRUE00

Latest PRQR Trades:

Date Shares Price
Jun 13, 2022 7:55 PM EST200$0.7361
Jun 13, 2022 7:56 PM EST100$0.7362
Jun 13, 2022 7:57 PM EST100$0.7362
Jun 13, 2022 7:58 PM EST100$0.7362
Jun 13, 2022 7:58 PM EST100$0.7362

ProQR Therapeutics N.V (PRQR) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465920076427/0001104659-20-076427-index.htm
2017-10-16UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1612940/000000000017036583/0000000000-17-036583-index.htm
2018-11-14UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1612940/000000000018035330/0000000000-18-035330-index.htm
2020-09-15UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1612940/000000000020008695/0000000000-20-008695-index.htm
2018-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000005341718000075/0000053417-18-000075-index.htm
2019-02-01SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000005341719000057/0000053417-19-000057-index.htm
2020-02-07SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000005341720000053/0000053417-20-000053-index.htm
2019-02-07SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000076999319000144/0000769993-19-000144-index.htm
2020-01-29SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000076999320000057/0000769993-20-000057-index.htm
2018-02-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000089375018000011/0000893750-18-000011-index.htm
2019-11-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000090221919000460/0000902219-19-000460-index.htm
2020-01-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000090221920000297/0000902219-20-000297-index.htm
2018-05-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000090266418002399/0000902664-18-002399-index.htm
2019-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000090266419000926/0000902664-19-000926-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000090266420000949/0000902664-20-000949-index.htm
2018-09-05424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000104746918005972/0001047469-18-005972-index.htm
2018-09-07424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000104746918006056/0001047469-18-006056-index.htm
2018-11-07F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1612940/000104746918007114/0001047469-18-007114-index.htm
2019-10-16424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000104746919005754/0001047469-19-005754-index.htm
2019-10-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000104746919005785/0001047469-19-005785-index.htm
2020-03-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000104746920001952/0001047469-20-001952-index.htm
2020-09-11F-3Registration statement by foreign private issuershttps://www.sec.gov/Archives/edgar/data/1612940/000104746920004838/0001047469-20-004838-index.htm
2020-09-22424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000104746920004951/0001047469-20-004951-index.htm
2018-04-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918023397/0001104659-18-023397-index.htm
2018-04-12SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000110465918023745/0001104659-18-023745-index.htm
2018-05-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918031925/0001104659-18-031925-index.htm
2018-05-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918033819/0001104659-18-033819-index.htm
2018-06-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918039614/0001104659-18-039614-index.htm
2018-06-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918043023/0001104659-18-043023-index.htm
2018-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918055202/0001104659-18-055202-index.htm
2018-09-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918055377/0001104659-18-055377-index.htm
2018-09-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918055828/0001104659-18-055828-index.htm
2018-10-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918064394/0001104659-18-064394-index.htm
2018-11-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918066682/0001104659-18-066682-index.htm
2018-11-15CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1612940/000110465918068781/0001104659-18-068781-index.htm
2018-12-046-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918071208/0001104659-18-071208-index.htm
2018-12-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918072104/0001104659-18-072104-index.htm
2018-12-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465918072684/0001104659-18-072684-index.htm
2019-01-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919000974/0001104659-19-000974-index.htm
2019-01-18SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000110465919002500/0001104659-19-002500-index.htm
2019-01-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919003863/0001104659-19-003863-index.htm
2019-01-296-K/AReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919004075/0001104659-19-004075-index.htm
2019-02-276-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919010937/0001104659-19-010937-index.htm
2019-03-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919013877/0001104659-19-013877-index.htm
2019-03-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919017423/0001104659-19-017423-index.htm
2019-04-156-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919021226/0001104659-19-021226-index.htm
2019-04-226-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919022641/0001104659-19-022641-index.htm
2019-05-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919027809/0001104659-19-027809-index.htm
2019-05-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919030802/0001104659-19-030802-index.htm
2019-07-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919042293/0001104659-19-042293-index.htm
2019-08-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919045300/0001104659-19-045300-index.htm
2019-08-28SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000110465919047735/0001104659-19-047735-index.htm
2019-09-096-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919049323/0001104659-19-049323-index.htm
2019-10-106-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919053649/0001104659-19-053649-index.htm
2019-10-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919054270/0001104659-19-054270-index.htm
2019-10-176-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919054650/0001104659-19-054650-index.htm
2019-11-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919062602/0001104659-19-062602-index.htm
2019-11-216-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919066218/0001104659-19-066218-index.htm
2019-12-116-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465919071667/0001104659-19-071667-index.htm
2020-01-27SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000110465920007219/0001104659-20-007219-index.htm
2020-01-306-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465920008366/0001104659-20-008366-index.htm
2020-03-316-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465920040802/0001104659-20-040802-index.htm
2020-05-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465920065862/0001104659-20-065862-index.htm
2020-06-246-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465920076427/0001104659-20-076427-index.htm
2020-07-146-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465920083487/0001104659-20-083487-index.htm
2020-07-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465920084882/0001104659-20-084882-index.htm
2020-09-16CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1612940/000110465920105661/0001104659-20-105661-index.htm
2020-10-056-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000110465920111968/0001104659-20-111968-index.htm
2018-01-26SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000113777418000023/0001137774-18-000023-index.htm
2019-01-31SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000113777419000021/0001137774-19-000021-index.htm
2020-02-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000113777420000027/0001137774-20-000027-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000114420418008773/0001144204-18-008773-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000114420419007793/0001144204-19-007793-index.htm
2018-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000117266118000535/0001172661-18-000535-index.htm
2017-10-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000119312517307976/0001193125-17-307976-index.htm
2017-10-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312517320152/0001193125-17-320152-index.htm
2017-11-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312517339835/0001193125-17-339835-index.htm
2017-11-13424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000119312517341047/0001193125-17-341047-index.htm
2017-11-136-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312517341076/0001193125-17-341076-index.htm
2017-11-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000119312517344271/0001193125-17-344271-index.htm
2017-11-15424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1612940/000119312517344284/0001193125-17-344284-index.htm
2017-11-166-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312517344796/0001193125-17-344796-index.htm
2017-11-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312517348180/0001193125-17-348180-index.htm
2017-11-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312517355798/0001193125-17-355798-index.htm
2017-12-296-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312517383514/0001193125-17-383514-index.htm
2018-02-126-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312518040210/0001193125-18-040210-index.htm
2018-02-206-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312518050379/0001193125-18-050379-index.htm
2018-02-286-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000119312518062399/0001193125-18-062399-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000119312519035943/0001193125-19-035943-index.htm
2019-02-15SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000119312519042040/0001193125-19-042040-index.htm
2020-02-11SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000119312520030570/0001193125-20-030570-index.htm
2018-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000142573818000015/0001425738-18-000015-index.htm
2018-09-17SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000149315218013367/0001493152-18-013367-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000149315219001952/0001493152-19-001952-index.htm
2019-02-22SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000149315219002422/0001493152-19-002422-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1612940/000149315220002410/0001493152-20-002410-index.htm
2018-03-3020-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1612940/000155837018002577/0001558370-18-002577-index.htm
2018-04-236-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000155837018003144/0001558370-18-003144-index.htm
2018-08-086-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000155837018006774/0001558370-18-006774-index.htm
2019-03-2820-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1612940/000155837019002525/0001558370-19-002525-index.htm
2019-08-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000155837019007370/0001558370-19-007370-index.htm
2020-02-266-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000155837020001395/0001558370-20-001395-index.htm
2020-03-3120-FAnnual and transition report of foreign private issuers [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1612940/000155837020003457/0001558370-20-003457-index.htm
2020-05-076-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000155837020005543/0001558370-20-005543-index.htm
2020-08-066-KReport of foreign issuer [Rules 13a-16 and 15d-16]https://www.sec.gov/Archives/edgar/data/1612940/000155837020009683/0001558370-20-009683-index.htm
2018-11-19EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1612940/999999999518002932/9999999995-18-002932-index.htm
2020-09-18EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1612940/999999999520002507/9999999995-20-002507-index.htm
2018-04-09CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1612940/999999999718004385/9999999997-18-004385-index.htm
2019-04-23CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1612940/999999999719003175/9999999997-19-003175-index.htm